Our Recommendations
New Publications
- Recomendaciones provisionales sobre el uso de la vacuna CanSinoBIO Ad5-nCoV-S [recombinante] (Convidecia™) contra la COVID-19: orientaciones provisionales, primera publicación: 19 de mayo de 2022 (2022)
- Good practice statement on the use of variant-containing COVID-19 vaccines (2022)
- WHO Science in 5 Episode #78 - mRNA technologies (2022)
- Interim recommendations for use of the Valneva VLA2001 vaccine against COVID 19: interim guidance (2022)
- Interim recommendations for use of the CanSinoBIO Ad5-nCoV-S [recombinant] vaccine (Convidecia™) against COVID-19: interim guidance, first issued 19 May 2022 (2022)
Filter
132
Featured
Recommendations
24
Language
Document type
Guidelines
44
Fact sheets
43
Studies & Reports
14
Resource Platforms
11
Manuals
7
Infographics
5
Situation Updates
4
Videos
3
Training Material
1
Countries / Regions
Germany
16
Brazil
8
Russia
8
West and Central Africa
6
East and Southern Africa
6
Argentina
6
India
6
Mozambique
3
Africa
3
Latin America and the Carribbean
2
Middle East and North Africa
2
Western and Central Europe
2
South Sudan
2
Turkey
1
Kazakhstan
1
Global
1
Haiti
1
Guinea-Bissau
1
France
1
United Kingdom
1
Portugal
1
Spain
1
South Korea
1
Belarus
1
Vietnam
1
Angola
1
Authors & Publishers
Publication Years
Category
Countries
55
Key Resources
2
Women & Child Health
1
The COVID-19 Vaccine (Whole Virion Inactivated) BBV152, COVAXIN® vaccine explainer includes key information on the vaccine specific requirements.
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th...
Interim Guidance October 2022. This addendum addresses some of the methodological aspects of VE evaluations that have been learned during the past year, as well as those that have become relevant in the current epidemiological setting of the COVID-19 pandemic. For some of the COVID-19 vaccine method...
29 April 2022
What are the new vaccines in the pipeline? What are the challenges to turning vaccines into vaccination ? What timelines can we expect for future vaccines? WHO’s Dr Katherine O’Brien explains in Science in 5.
Esta orientação provisória foi desenvolvida com base na recomendação emitida pelo Grupo Consultivo Estratégico de Especialistas (SAGE) em imunização, em sua reunião extraordinária de 5 de janeiro de 2021, e atualizada durante sua reunião extraordinária de 27 de maio de 2021 (2), sendo no...
orientaciones provisionales, primera publicación: 24 de mayo de 2021, actualización: 21 de octubre de 2021, actualización: 15 de marzo de 2022
COVID-19 vaccine tracker and landscape
recommended
The COVID-19 vaccine tracker and landscape compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their progress through the pipeline.
The COVID-19 vaccine tracker:
Provides summary tables of COVID-19 vaccine candidates in both clinical and pre-...
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
mRNA technologies. What is their future and scope, and what are the challenges that countries might face in rolling them out? Hello and welcome to Science in5. I'm Vismita Gupta-Smith. We are talking to Dr.Soumya Swaminathan today. Soumya, talk to us about mRNA technologies. What is the future?
9 Febr. 2022
The COVID Covovax™ (SIIPL) and Nuvaxovid™ (Novavax) vaccine explainer includes key vaccine specific information on the vaccine specific requirements.
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat...
Los datos preliminares de eficacia se infirieron mediante un enfoque de “inmunogenicidad puente”, en el que los títulos neutralizantes obtenidos después de la vacuna en niños y niñas de 5 a 11 años se compararon con los títulos obtenidos en adolescentes de 16 a 25 años (en quienes se hab...
These are standing orders for eligible nurses and healthcare professionals to administer the Moderna COVID-19 vaccine to persons 18 years of age and older
Vacunas
recommended
COVID Reference 23 May 2021
Februrar 2021
